Research any topic before you write.
Find related topics. | Discover entities. | See connections. | Build a topical map.
Lecanemab, sold under the brand name Leqembi, is a monoclonal antibody medication used for the treatment of mild Alzheimer's disease. Lecanemab is an amyloid beta-directed antibody. It is given via intravenous infusion or subcutaneous injection. In clinical trials, it demonstrated small or no clinically significant efficacy in Alzheimer's disease. The…
History, Community, Culture & Applications
Explore the main themes, entities and connections around Lecanemab. Start with the topic map, then use the sections below for research and deeper semantic analysis.
Start with a few of the strongest sections from the source topic. These are research directions, not a list of keywords you must use.
High-confidence facts extracted from structured source data. Use them as anchors for further research.
Browse the full topic structure. Each item opens a new analysis centered on that subject.
Deeper signals for content research, entity SEO and topical coverage. The plain-language headings explain what each technical view is useful for.
See the strongest relationship patterns around the current topic before diving into the raw triples.
Use these terms to understand the vocabulary surrounding the topic, not as a checklist for keyword stuffing.
alzheimer's disease treatment amyloid clinical people fda mild eisai may approval participants small leqembi dementia placebo antibody cognitive 2023 2025
| Subject | Predicate | Object | Confidence | Src |
|---|---|---|---|---|
| Lecanemab | AHFS/Drugs.com | Monograph | 1.00 | infobox |
| Lecanemab | ATC code | N06DX04 (WHO) | 1.00 | infobox |
| Lecanemab | CAS Number | 1260393-98-3 | 1.00 | infobox |
| Lecanemab | ChemSpider | none | 1.00 | infobox |
| Lecanemab | DrugBank | DB14580 | 1.00 | infobox |
| Lecanemab | Formula | C6544H10088N1744O2032S46 | 1.00 | infobox |
| Lecanemab | KEGG | D11678 | 1.00 | infobox |
| Lecanemab | Legal status | CA: ℞-only / Schedule D | 1.00 | infobox |
| Lecanemab | Legal status | US: ℞-only | 1.00 | infobox |
| Lecanemab | Legal status | EU: Rx-only | 1.00 | infobox |
| Lecanemab | Legal status | Rx-only | 1.00 | infobox |
| Lecanemab | License data | US DailyMed: Lecanemab | 1.00 | infobox |
| Lecanemab | MedlinePlus | a623004 | 1.00 | infobox |
| Lecanemab | Molar mass | 147181.62 g·mol−1 | 1.00 | infobox |
| Lecanemab | Other names | BAN2401, lecanemab-irmb | 1.00 | infobox |
| Lecanemab | Routes of administration | Intravenous, subcutaneous | 1.00 | infobox |
| Lecanemab | Source | Humanized | 1.00 | infobox |
| Lecanemab | Target | Amyloid beta | 1.00 | infobox |
| Lecanemab | Trade names | Leqembi | 1.00 | infobox |
| Lecanemab | Type | Whole antibody | 1.00 | infobox |
| Lecanemab | UNII | 12PYH0FTU9 | 1.00 | infobox |
| Lecanemab | is a | amyloid beta-directed antibody | 0.90 | text |
| Lecanemab | is a | humanized monoclonal antibody consisting of a humanized version of a mouse antibody | 0.90 | text |
These clusters group vocabulary that occurs around closely connected concepts in the source material.
Bridges can reveal useful research angles that are easy to miss in a flat list of related terms.